Marshall Wace’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Marshall Wace’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-316,146	Closed	-$359K	–	3996
2022 Q1	$359K	Sell	316,146 -284,093	-47%	-$339K	﹤0.01%	2915
2021 Q4	$1.35M	Buy	600,239 +584,003	+3,597%	+$1.47M	﹤0.01%	2306
2021 Q3	$56K	Sell	16,236 -130,506	-89%	-$402K	﹤0.01%	2933
2021 Q2	$438K	Sell	146,742 -545,150	-79%	-$1.72M	﹤0.01%	2190
2021 Q1	$2.24M	Buy	+691,892	New	+$2.31M	0.01%	1269
2019 Q2	–	Sell	-18,606	Closed	-$35K	–	1969
2019 Q1	$35K	Sell	18,606 -24,065	-56%	-$35.2K	﹤0.01%	1578
2018 Q4	$50K	Buy	+42,671	New	+$76.7K	﹤0.01%	1444
2016 Q2	–	Sell	-49,589	Closed	-$261K	–	1218
2016 Q1	$261K	Buy	+49,589	New	+$303K	﹤0.01%	942
2015 Q1	–	Sell	-15,336	Closed	-$259K	–	966
2014 Q4	$259K	Sell	15,336 -4,130	-21%	-$60.1K	﹤0.01%	719
2014 Q3	$261K	Buy	+19,466	New	+$232K	﹤0.01%	729

Other funds holding INFI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Marshall Wace's INFI Position: Q2 2022 in Review

Marshall Wace sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2022, closing a stake of 316,146 shares — an estimated $359K sold.

Marshall Wace first reported a position in INFI in Q3 2014 and held it in 10 quarters. The position peaked at $2.24M in Q1 2021. 77 funds tracked by Wall St. Rank hold INFI as of Q2 2022.

Marshall Wace reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
Marshall Wace sold 316,146 Infinity Pharmaceuticals, Inc. shares in Q2 2022, an estimated $359K.
Marshall Wace first reported a position in Infinity Pharmaceuticals, Inc. in Q3 2014 and held it in 10 quarters.
Marshall Wace's Infinity Pharmaceuticals, Inc. position peaked at $2.24M in Q1 2021.
77 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2022.

Based on Marshall Wace's 13F filing for Q2 2022, filed 15 Aug 2022.